Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Bone Disorders01:29

Bone Disorders

8.0K
Aging and its effect on bone remodeling is the most common cause of bone disorders. In young and healthy people, bone deposition and resorption happen at an equal rate to maintain optimal bone health.
Bone deposition is also affected by the levels of sex hormones like estrogen and testosterone that promote osteoblast activity and bone matrix synthesis. When the level of these hormones decreases due to aging, it causes a reduction in bone deposition. As a result, bone resorption by osteoclasts...
8.0K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

3.6K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.6K
Bone Remodeling01:40

Bone Remodeling

34.4K
Bone remodeling is a continuous and balanced process of bone resorption by osteoclasts and bone formation by osteoblasts. In adults, it helps maintain bone mass and calcium homeostasis. While mechanical stress can stimulate turnover as part of the normal maintenance and reparative process, several hormones also regulate bone remodeling.
34.4K
Cancer Therapies02:49

Cancer Therapies

8.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
8.6K
Osteoclasts in Bone Remodeling01:31

Osteoclasts in Bone Remodeling

3.9K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.9K
Cancer Survival Analysis01:21

Cancer Survival Analysis

870
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
870

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Non-metastatic breast cancer patients discontinuing aromatase inhibitor on denosumab: what next?

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same author

Characterizing types and circumstances of fractures in the Canadian Multicentre Osteoporosis Study.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2025
Same author

Geographic variation in bone mineral density and prevalent fractures in the Canadian longitudinal study on aging.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2023
Same author

Publisher Correction: International consensus on the non-pharmacological and non-surgical management of osteoporotic vertebral fractures.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2023
Same author

International consensus on the non-pharmacological and non-surgical management of osteoporotic vertebral fractures.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2023
Same author

Discrepancies Between Osteoporotic Fracture Evaluations in Men Based on German (DVO) Osteoporosis Guidelines or the FRAX Score.

Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association·2022
Same journal

Correction to: Melatonin at pharmacological concentrations suppresses osteoclastogenesis via the attenuation of intracellular ROS.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same journal

Letter to the Editor: multiplicity, microbiome interventions, and measurement biases in bone health biomarkers.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same journal

Association between myosteatosis and bone mineral density in postmenopausal women.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same journal

Author response to the letter to the editor regarding "Hip Response to Romosozumab in Glucocorticoid Users: Beyond Systemic Bone Turnover Markers".

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same journal

Preventing post-denosumab bone loss with zoledronate: a 2-year randomized trial in post-menopausal women without and with pre-exposure to bisphosphonates.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
Same journal

Revisiting the Osteoporosis Self-Assessment Tool (OST): evidence from a multi-cohort study in Asia supporting age-dependent thresholds.

Osteoporosis international : a journal established as result of cooperation between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA·2026
See all related articles

Related Experiment Video

Updated: May 6, 2026

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation
07:17

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation

Published on: April 14, 2016

88.0K

Cancer-associated bone disease.

R Rizzoli1, J-J Body, M-L Brandi

  • 1Division of Bone Diseases, Geneva University Hospitals and Faculty of Medicine, Geneva, Switzerland, Rene.Rizzoli@unige.ch.

Osteoporosis International : a Journal Established As Result of Cooperation Between the European Foundation for Osteoporosis and the National Osteoporosis Foundation of the USA
|October 23, 2013
PubMed
Summary
This summary is machine-generated.

Cancer frequently impacts bone, leading to fragility from the disease or its treatments. Bone-modifying agents and clinical guidelines help prevent and manage cancer-related bone disease and skeletal events.

More Related Videos

Models of Bone Metastasis
08:49

Models of Bone Metastasis

Published on: September 4, 2012

42.1K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

6.1K

Related Experiment Videos

Last Updated: May 6, 2026

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation
07:17

Murine Hind Limb Long Bone Dissection and Bone Marrow Isolation

Published on: April 14, 2016

88.0K
Models of Bone Metastasis
08:49

Models of Bone Metastasis

Published on: September 4, 2012

42.1K
Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
06:32

Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model

Published on: November 4, 2022

6.1K

Area of Science:

  • Oncology
  • Bone Metabolism
  • Cancer Therapeutics

Background:

  • Bone is a common site for cancer metastasis and treatment side effects, leading to fragility.
  • Cancer-induced bone disease arises from primary cancer or therapies like chemotherapy and hormone deprivation.
  • Skeletal-related events (SREs) include fractures, spinal cord compression, and pain, impacting patient quality of life.

Purpose of the Study:

  • To provide an International Osteoporosis Foundation (IOF) position paper on bone diseases and cancer.
  • To summarize existing position papers from other organizations on this topic.
  • To guide physicians in managing cancer-related bone disease and preventing SREs.

Main Methods:

  • Review of existing literature and guidelines on cancer and bone disease.
  • Synthesis of evidence regarding bone-modifying agents (bisphosphonates, denosumab).
  • Development of evidence-based care pathways for clinical decision-making.

Main Results:

  • Bone-modifying agents are effective in preventing and delaying cancer-related bone disease and SREs.
  • Guidelines assist physicians in managing patients with bone metastases and treatment-induced bone loss.
  • Early intervention and evidence-based pathways are crucial for optimal patient outcomes.

Conclusions:

  • Effective management strategies exist for cancer-related bone disease.
  • Guidelines and bone-modifying agents play a vital role in preventing SREs and bone loss.
  • A multidisciplinary approach is essential for addressing the complexities of bone disease in cancer patients.